Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

Core Viewpoint - Mangoceuticals Inc. has entered into an Intellectual Property Purchase Agreement to acquire Smokeless Technology Corp., marking a strategic expansion into the oral pouch delivery market, which is rapidly growing in the consumer wellness and alternative nicotine sectors [1][2]. Company Overview - Mangoceuticals focuses on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx [1][10]. - The company aims to integrate Smokeless Tech's stimulant formulations with pharmaceutical ingredients to enhance its product offerings [2][5]. Market Insights - The U.S. nicotine pouch market reached $3.13 billion in 2024, with Zyn as the category leader at over $1.6 billion in sales [3]. - The global oral pouch market is projected to exceed $37.34 billion by 2032, indicating significant growth potential for functional wellness pouches [3]. Strategic Growth Plans - The acquisition is expected to unlock new growth phases for Mangoceuticals, aligning with the company's mission to develop health and wellness products with executable business models [4]. - The company plans to leverage its established distribution network and upcoming product launches, such as Diabetinol, to enhance its market position [6]. Leadership Enhancement - Tim Corkum, a veteran in Consumer Packaged Goods, has joined the management team to drive the development of new non-pharmaceutical and nutraceutical products [4][5][8]. - Corkum's experience includes leadership roles at JUUL Labs Canada and Philip Morris International, focusing on smoke-free initiatives and business development [8][9].